MET and hepatocellular carcinoma: Upregulation of the HGF/c-MET axis has determined acquired resistance to lenvatinib in a preclinical model of HCC [52], suggesting its potential role as a therapeutic target to overcome lenvatinib resistance, particularly in light of the high percentage of HCC patients overexpressing these two molecules [53].